Mersana Therapeutics (MRSN) Q4 results:
Revenues: $0.04M (-96.7%).
Net loss: ($16.2M) (+27.7%); loss/share: ($0.34) (+64.9%); Quick Assets: $99.8M (+42.4%).
XMT-1536 interim Phase 1 dose expansion data to be presented in Q2 with more mature data expected in H2.
Previously: Mersana Therapeutics EPS beats by $0.04, misses on revenue (Feb. 28)
https://seekingalpha.com/news/3546936-mersana-therapeutics-q4-top-line-down-97
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.